30
Participants
Start Date
March 30, 2025
Primary Completion Date
April 1, 2028
Study Completion Date
April 1, 2028
Tislelizumab
recombinant humanized anti-PD-1 monoclonal antibody for injection; 200mg ivdrip,d1, q3w
S-1
40\~60mg Bid,d1\~14, q3w
Oxaliplatin
130mg/m2,iv drip for 2h,d1, q3w
Docetaxel
Docetaxel at a dose of 20 mg/m2 or paclitaxel at a dose of 40 mg/m2 dissolved in 3-5 L of normal saline heated to 43 ± 0.5 °C for HIPEC.(d01-d03,qd,before first cycle of Tislelizumab and SOX)
Paclitaxel
Paclitaxel at a dose of 40 mg/m2 or docetaxel at a dose of 20 mg/m2 dissolved in 3-5 L of normal saline heated to 43 ± 0.5 °C for HIPEC.(d01-d03,qd,before first cycle of Tislelizumab and SOX)
Fudan University
OTHER